Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cocconi

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Future Oncology (London, England)|June 22, 2016
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trialGiandomenico Roviello, Manuela Milani, Angela Gobbi, et al.
GMS Hygiene and Infection Control|December 27, 2021
A European approach to infection prevention and control goalsMartin Exner, Bärbel Christiansen, Roberto Cocconi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised studyM Colozza, G Bisagni, A M Mosconi, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2020
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatmentA Ianza, F Giudici, C Pinello, et al.
Lancet (London, England)|April 28, 1999
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapyR Passalacqua, F Campione, C Caminiti, et al.
Breast (Edinburgh, Scotland)|May 4, 2019
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trialsS P Corona, G Roviello, C Strina, et al.
The New England Journal of Medicine|October 7, 1982
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanomaU Veronesi, J Adamus, C Aubert, et al.
The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.
Soft Matter|May 13, 2025
Intelligent soft matter: towards embodied intelligenceVladimir A Baulin, Achille Giacometti, Dmitry A Fedosov, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Future Oncology (London, England)|June 22, 2016
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trialGiandomenico Roviello, Manuela Milani, Angela Gobbi, et al.
GMS Hygiene and Infection Control|December 27, 2021
A European approach to infection prevention and control goalsMartin Exner, Bärbel Christiansen, Roberto Cocconi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised studyM Colozza, G Bisagni, A M Mosconi, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2020
ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatmentA Ianza, F Giudici, C Pinello, et al.
Lancet (London, England)|April 28, 1999
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapyR Passalacqua, F Campione, C Caminiti, et al.
Breast (Edinburgh, Scotland)|May 4, 2019
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trialsS P Corona, G Roviello, C Strina, et al.
The New England Journal of Medicine|October 7, 1982
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanomaU Veronesi, J Adamus, C Aubert, et al.
The New England Journal of Medicine|March 12, 2004
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerR Charles Coombes, Emma Hall, Lorna J Gibson, et al.
Soft Matter|May 13, 2025
Intelligent soft matter: towards embodied intelligenceVladimir A Baulin, Achille Giacometti, Dmitry A Fedosov, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 16